Good news against cancer! Cabozantinib’s miraculous effects

A major study involving658 adults with advanced renal cell carcinoma shows that cabozantinib can effectively extend the time patients survive without disease progression (PES). In the study, cabozantinib was compared with the cancer drug everolimus. Patients treated with cabozantinib lived an average of 7.4 months without disease progression. In addition, the results showed that patients treated with cabozantinib lived longer overall than those treated with everolimus.

A second major study shows cabozantinib is effective in adults with previously untreated renal cell carcinoma that is locally advanced or has spread to other parts of the body. The study involved 157 patients and compared cabozantinib with sunitinib, another cancer drug. Patients treated with cabozantinib lived an average of 8.6 months without disease progression, while those treated with sunitinib lived an average of 5.3 months.

A major study involving707 adult patients with hepatocellular carcinoma who had been treated with sorafenib showed that cabozantinib was effective in extending patient survival (PES). In this study, cabozantinib was compared with a placebo, a dummy treatment. Patients who received cabozantinib lived for an average of 10.2 months, while those who received placebo lived for an average of 8.0 months.

One major study involved 187 adults with differentiated thyroid cancer whose disease progressed despite previous treatment. Patients who received cabozantinib lived an average of 11 months without disease progression, compared with just 2 months for those who received a placebo. Additionally, the results showed that patients treated with cabozantinib lived longer overall than those treated with placebo.

Cabozantinib was shown to be effective in a major study involving 330 adults with medullary thyroid cancer, which cannot be treated with surgery and has spread or spread to other parts of the body. Cabozantinib was administered once daily at an initial dose of 140 mg (dose reduced if necessary due to side effects) and compared with placebo (dummy treatment). The primary measure of effectiveness was progression-free survival (how long a patient lived before their disease worsened): 11.2 months for those who received cabozantinib versus 4.0 months for those who received placebo.

The original drug Cabozantinib is not marketed in the country and therefore cannot be included in medical insurance. The original cabozantinib drug marketed overseas includes Japanese, Turkish and European versions. The price of tablets may be more than 30,000 yuan, and the price of capsule preparations may be more than 40,000 yuan (prices may fluctuate due to exchange rates). There are also generic drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. For example, the price of pharmaceuticals produced by Bangladeshi pharmaceutical factories may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), which is relatively cheap.